Search Result

Results for "

TLR9 agonist

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Toll-like Receptor (TLR) (49) Apoptosis (5) Bacterial (3) CXCR (1) IFNAR (2) Interleukin Related (4) MHC (1) Mitosis (1) NO Synthase (3) Reference Standards (1) TNF Receptor (1)
By Research Areas:	Cancer (23) Cardiovascular Disease (2) Infection (7) Inflammation/Immunology (37) Neurological Disease (2)
Oligonucleotides:	CpG ODNs (41) Antisense Oligonucleotides (6)

Inhibitors & Agonists

Inhibitory Antibodies

Oligonucleotides

Targets Recommended: Toll-like Receptor (TLR)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-146245

ODN 1826 Maximum Cited Publications 10 Publications Verification CpG 1826	Toll-like Receptor (TLR) Apoptosis NO Synthase	Cardiovascular Disease Inflammation/Immunology Cancer
ODN 1826 is a class B CpG ODN (oligodeoxynucleotide) and *TLR9* agonist. ODN 1826 induces NO and iNOS production and enhances Apoptosis. ODN 1826 enhances immune surveillance. ODN 1826 increases aortic atherosclerotic plaque size. ODN 1826 has antitumor activity against lung cancer, glioma and melanoma .

HY-146244

Agatolimod 1 Publications Verification ODN 2006; PF-3512676; CpG 7909; ODN 7909	Toll-like Receptor (TLR) Bacterial NO Synthase Apoptosis	Infection Cancer
Agatolimod ((ODN 2006; PF-3512676; CpG 7909)) is a *TLR9* agonist and immunomodulator with an EC₅₀ of 180 nM against human *TLR9. Agatolimod activates and upregulates the expression of both TLR9* and *TLR6, and mediates downstream signaling pathways via IRAK4, IRF5, IRF7. Agatolimod induces Th1-type innate and adaptive immune responses, activates various immune cells and promotes antigen presentation, regulates antibody levels and immune cell infiltration, upregulates the secretion of multiple cytokines, induces apoptosis and cell cycle arrest, enhances cytotoxicity, and clears intracellular Salmonella. Agatolimod is applicable to research on COVID-19*, breast cancer, lung adenocarcinoma, HPV-related tumors, melanoma, and salmonellosis .

HY-150724

ODN 1018 2 Publications Verification 1018 ISS	Toll-like Receptor (TLR)	Inflammation/Immunology
ODN 1018 (1018 ISS) is a *TLR9* agonist and immune modulator. ODN 1018 exhibits adjuvant activity and augments CD8+ T cell responses with LNP-encapsulated OVA peptides. ODN 1018 triggers sustained suppression of allergic airway inflammation. ODN 1018 can be used for the research of allergic asthma and systemic lupus erythematosus .

HY-150218

Agatolimod sodium 1 Publications Verification ODN 2006 sodium; ODN 7909 sodium; PF-3512676 sodium; CpG 7909 sodium	Toll-like Receptor (TLR)	Cancer
Agatolimod sodium (ODN 2006) is a class B CpG ODN and is a *TLR9* agonist. Agatolimod sodium can be used as vaccine adjuvant. Agatolimod sodium can be used for the research of cancer. Sequence: 5’-TCGTCGTTTTGTCGTTTTGTCGTT-3’ .

HY-150743

ODN 2395	Toll-like Receptor (TLR)	Infection Inflammation/Immunology
ODN 2395 is a C class oligodeoxynucleotide and can be used as vaccine adjuvant. ODN 2395 is also a *TLR9* agonist. ODN 2395 can be used in the research of immunological vaccines. Sequence: 5'-tcgtcgttttcggcgc:gcgccg-3' (Note: The bases are phosphorothioate; ODN 2395 contains the partial palindromic sequence cggcgc:gcgccg) .

HY-146245C

ODN 1826 sodium Maximum Cited Publications 10 Publications Verification CpG 1826 sodium	Toll-like Receptor (TLR) Apoptosis NO Synthase	Cardiovascular Disease Inflammation/Immunology Cancer
ODN 1826 sodium is a class B CpG ODN (oligodeoxynucleotide) and *TLR9* agonist. ODN 1826 sodium induces NO and iNOS production and enhances Apoptosis. ODN 1826 sodium enhances immune surveillance. ODN 1826 sodium increases aortic atherosclerotic plaque size. ODN 1826 sodium has antitumor activity against lung cancer, glioma and melanoma .

HY-150741

ODN 2216 1 Publications Verification	Toll-like Receptor (TLR) IFNAR Interleukin Related	Infection Inflammation/Immunology Cancer
ODN 2216 is a type A CpG oligodeoxynucleotide vaccine adjuvant and a *TLR9* agonist. ODN 2216 interacts with *TLR9* in the lysosomes of CD4 ⁺ T cells and activates feedback-dependent signaling pathways. ODN 2216 induces the production of type I interferons, IL-6 and TGF-β via the IRAK4/IRF7 axis, while increasing intracellular ATP levels. ODN 2216 not only induces the differentiation of CD4 ⁺ T cells into anti-inflammatory Th3-like regulatory phenotypes to inhibit autologous proliferation, but also enhances the specific CD8 ⁺ T cell-mediated cytotoxicity against Mammaglobin-A in breast cancer cells. ODN 2216 is widely used in studies related to breast cancer and systemic lupus erythematosus .

HY-150750

ODN M362	Toll-like Receptor (TLR) Apoptosis	Inflammation/Immunology Cancer
ODN M362, a class C oligodeoxynucleotide, is a *TLR-9* agonist and can be used as a vaccine adjuvant. ODN M362 induces cancer cell apoptosis .

HY-150724C

ODN 1018 sodium 2 Publications Verification 1018 ISS sodium	Toll-like Receptor (TLR)	Inflammation/Immunology
ODN 1018 (1018 ISS) sodium is a *TLR9* agonist and immune modulator. ODN 1018 sodium exhibits adjuvant activity and augments CD8+ T cell responses with LNP-encapsulated OVA peptides. ODN 1018 sodium triggers sustained suppression of allergic airway inflammation. ODN 1018 sodium can be used for the research of allergic asthma and systemic lupus erythematosus .

HY-150741C

ODN 2216 sodium 1 Publications Verification	Toll-like Receptor (TLR)	Cancer
ODN 2216 sodium is a type A CpG oligodeoxynucleotide vaccine adjuvant and a *TLR9* agonist. ODN 2216 sodium interacts with *TLR9* in the lysosomes of CD4 ⁺ T cells and activates feedback-dependent signaling pathways. ODN 2216 sodium induces the production of type I interferons, IL-6 and TGF-β via the IRAK4/IRF7 axis, while increasing intracellular ATP levels. ODN 2216 sodium not only induces the differentiation of CD4 ⁺ T cells into anti-inflammatory Th3-like regulatory phenotypes to inhibit autologous proliferation, but also enhances the specific CD8 ⁺ T cell-mediated cytotoxicity against Mammaglobin-A in breast cancer cells. ODN 2216 sodium is widely used in studies related to breast cancer and systemic lupus erythematosus .

HY-150217

CpG ODN 10101 2 Publications Verification ODN 10101	Toll-like Receptor (TLR)	Infection Inflammation/Immunology
CpG ODN 10101 (ODN 10101; CPG 10101) is a selective agonist targeting TLR9, a synthetic oligodeoxynucleotide modified with phosphate thioester. CpG ODN 10101 activates B cells and plasmacytoid dendritic cells (pDCs), inducing the production of cytokines and chemokines such as interferon-IFN-α, interferon-inducible protein IP-10, and 2'5'-oligoadenylate synthase (2'5'-OAS), regulating innate immunity and promoting Th1 adaptive immune responses. CpG ODN 10101 also possesses antiviral properties and enhances vaccine immunogenicity, making it suitable as an immunomodulator and vaccine adjuvant for vaccine development in chronic hepatitis C and infectious diseases such as melioidosis, pertussis, and respiratory syncytial virus (RSV) .

HY-150726

ODN 1668 1 Publications Verification	Toll-like Receptor (TLR) Bacterial	Infection Neurological Disease Inflammation/Immunology
ODN 1668, a class B CpG ODN (oligodeoxynucleotide), is a *TLR-9* agonist. ODN 1668 has strong immune regulatory properties, can enhance the level of antibody IgG2 subtype, promote the immune response of T cells and B cells, and can be used in the study of vaccine adjuvants. In addition, CpG ODN 1668 induces an antimicrobial immune response via a CaTLR9 dependent pathway in groupers. Sequence: 5'-tccatgacgttcctgatgct-3’ .

HY-150726C

ODN 1668 sodium 1 Publications Verification	Toll-like Receptor (TLR) Bacterial	Infection Neurological Disease Inflammation/Immunology
ODN 1668 sodium, a class B CpG ODN (oligodeoxynucleotide), is a *TLR-9* agonist. ODN 1668 sodium has strong immune regulatory properties, can enhance the level of antibody IgG2 subtype, promote the immune response of T cells and B cells, and can be used in the study of vaccine adjuvants. In addition, CpG ODN 1668 sodium induces an antimicrobial immune response via a CaTLR9 dependent pathway in groupers. Sequence: 5'-tccatgacgttcctgatgct-3’ .

HY-150750A

ODN M362 sodium	Toll-like Receptor (TLR) Apoptosis Interleukin Related TNF Receptor IFNAR	Inflammation/Immunology Cancer
ODN M362 sodium is a *TLR9* agonist that acts as a vaccine adjuvant. ODN M362 sodium activates mouse splenocytes, induces apoptosis in human hepatocellular carcinoma cells, upregulates proinflammatory cytokines in human hepatocellular carcinoma cells, and inhibits the proliferation of human hepatocellular carcinoma cells. ODN M362 sodium upregulates the expression of *TLR9/TLR6*, activates downstream signaling pathways via IRAK4 and IRF7, and strongly amplifies antigen-specific cellular immune responses to participate in innate immune activation. ODN M362 sodium can be used in research related to hepatocellular carcinoma and breast cancer .

HY-150217A

CpG ODN 10101 sodium 2 Publications Verification ODN 10101 sodium	Toll-like Receptor (TLR)	Infection
CpG ODN 10101 sodium, a synthetic oligodeoxynucleotide (ODN), is a toll-like receptor 9 (TLR9) agonist. CpG ODN 10101 sodium is a potent inducer of cytokine/chemokine expression ex vivo when used in combination with HH2(VQLRIRVAVIRA-NH2). CpG ODN 10101 sodium induces IFN- secretion from dendritic cells (DCs) and stimulates B-cells.CpG ODN 10101 sodium has antiviral and immunomodulatory properties that can influence chronic infection with HCV .

HY-150748A

ODN D-SL01 sodium	Toll-like Receptor (TLR)	Cancer
ODN D-SL01 sodium, a class B CpG ODN (oligodeoxynucleotide), is a *TLR9* agonist. ODN D-SL01 sodium has strong immunostimulatory activity in a variety of vertebrate species and has anticancer activity. ODN D-SL01 sequence: 5'- T-C-G-C-G-A-C-G-T-T-C-G-C-C-C-G-A-C-G-T-T-C-G-G-T-A-3' .

HY-101929

CU-CPT17e 3 Publications Verification	Toll-like Receptor (TLR)	Inflammation/Immunology Cancer
CU-CPT17e is a potent multi-Toll-like receptor (TLR) agonist that activates *TLR3, TLR8, and TLR9*.

HY-P991257

MK-1966 1 Publications Verification	Interleukin Related CXCR MHC	Cancer
MK-1966 is an anti-IL-10 antibody. MK-1966 inhibits secretion of cytokines from activated macrophages, production of CC and CXC chemokines, and a TH1 response, down-regulates MHC and costimulatory molecules on dendritic cells (DCs), and induces regulatory T cells. MK-1966 can be used for the research of cancer , such as gastric cancer .

HY-150724B

FITC-labeled ODN 1018 sodium	Toll-like Receptor (TLR)	Inflammation/Immunology
FITC-labeled ODN 1018 (sodium),an oligodeoxynucleotide, is a *TLR-9* agonist. FITC-labeled ODN 1018 (sodium) can be used to evaluate CpG ODN cellular uptake and localization by confocal laser-scanning microscopy (excitation 495 nm, emission 520 nm) or flow cytometry.

HY-150743A

Biotin-labeled ODN 2395 sodium	Toll-like Receptor (TLR)	Inflammation/Immunology
Biotin-labeled ODN 2395 (sodium), a C class oligodeoxynucleotide, is a *TLR9* agonist. Biotin-labeled ODN 2395 (sodium) can be used to evaluate CpG ODN cellular uptake and localization using a biotin detection system and light microscopy.

HY-148511A

Vidutolimod sodium CMP-001 sodium	Toll-like Receptor (TLR)	Cancer
Vidutolimod sodium is a CpG-A oligodeoxynucleotide. Vidutolimod sodium is a Toll-like receptor 9 (TLR9) agonist, which activates plasmacytoid dendritic cells (pDCs) and triggers interferon alpha (IFNα) release, leading to a cascade of anti-tumor immune effects.

HY-146245F

FAM-labeled ODN 1826 sodium 1 Publications Verification	Toll-like Receptor (TLR)	Inflammation/Immunology Cancer
FAM-labeled ODN 1826 sodium, a class B CpG ODN (oligodeoxynucleotide), is a *TLR9* agonist. FAM-labeled ODN 1826 sodium can be used to evaluate CpG ODN cellular uptake and localization by confocal laser-scanning microscopy or flow cytometry.

HY-146245A

Biotin-labeled ODN 1826 sodium	Toll-like Receptor (TLR)	Inflammation/Immunology
Biotin-labeled ODN 1826 (sodium), a class B CpG ODN (oligodeoxynucleotide), is a *TLR9* agonist. Biotin-labeled ODN 1826 (sodium) can be used to evaluate CpG ODN cellular uptake and localization using a biotin detection system and light microscopy.

HY-150743C

ODN 2395 sodium	Toll-like Receptor (TLR)	Inflammation/Immunology
ODN 2395 sodium is a C class oligodeoxynucleotide and can be used as vaccine adjuvant. ODN 2395 sodium is also a *TLR9* agonist. ODN 2395 sodium can be used in the research of immunological vaccines. Sequence: 5'-tcgtcgttttcggcgc:gcgccg-3' .

HY-150743B

FITC-labeled ODN 2395 sodium	Toll-like Receptor (TLR)	Inflammation/Immunology
FITC-labeled ODN 2395 (sodium), a C class oligodeoxynucleotide, is a *TLR9* agonist. FITC-labeled ODN 2395 (sodium) can be used to evaluate CpG ODN cellular uptake and localization by confocal laser-scanning microscopy (excitation 495 nm, emission 520 nm) or flow cytometry.

HY-150742A

ODN 2336 sodium	Toll-like Receptor (TLR)	Inflammation/Immunology
ODN 2336 sodium is a A-Class CpG ODN (oligodeoxynucleotides), is a potent *TLR9* agonist. ODN 2336 sodium induces the production of IFN-α. ODN 2336 sodium up-regulates the expression of IP-10 mRNA and IL-18 mRNA. ODN 2336 sodium can be used as adjuvant of vaccines .

HY-150212

Tilsotolimod IMO-2125	Toll-like Receptor (TLR)	Inflammation/Immunology Cancer
Tilsotolimod (IMO-2125) is a *TLR9* agonist. Tilsotolimod activates the *TLR9* signaling pathway, triggers downstream pro-inflammatory and immunostimulatory pathways, enhances the uptake and killing of cancer cells, and induces adaptive immune responses. Tilsotolimod is applicable to research related to melanoma and colorectal cancer .

HY-150212A

Tilsotolimod sodium IMO-2125 sodium	Toll-like Receptor (TLR)	Inflammation/Immunology Cancer
Tilsotolimod (IMO-2125) sodium is a *TLR9* agonist. Tilsotolimod sodium activates the *TLR9* signaling pathway, triggers downstream pro-inflammatory and immunostimulatory pathways, enhances the uptake and killing of cancer cells, and induces adaptive immune responses. Tilsotolimod sodium is applicable to research related to melanoma and colorectal cancer .

HY-146244A

Biotin-labeled agatolimod sodium	Toll-like Receptor (TLR)	Inflammation/Immunology
Biotin-labeled agatolimod (sodium), a class B CpG ODN (oligodeoxynucleotide), is a *TLR9* agonist. Biotin-labeled agatolimod (sodium) can be used to evaluate CpG ODN cellular uptake and localization using a biotin detection system and light microscopy.

HY-150741B

FITC-labeled ODN 2216 sodium	Toll-like Receptor (TLR) Interleukin Related	Inflammation/Immunology
FITC-labeled ODN 2216 (sodium) is a human-specific *TLR9* (toll-like receptor 9) ligand or agonist. FITC-labeled ODN 2216 (sodium) can be used to evaluate CpG ODN cellular uptake and localization by confocal laser-scanning microscopy (excitation 495 nm, emission 520 nm) or flow cytometry.

HY-177058

DSP30	Toll-like Receptor (TLR) Mitosis	Inflammation/Immunology
DSP30 is a phosphorothioate cpG-oligodeoxynucleotide and a *TLR9* agonist. DSP30 can activate immune system cells, including B cells and dendritic cells, by inducing proliferation and cytokine production.DSP30 can enhance the immunosuppressive function of bone marrow-multipotent mesenchymal stromal cells (BM-MSC). DSP30 combined with interleukin 2 (IL2) is an effective mitotic stimulant in B-cell disorders. DSP30 can be used for the genetic characteristic research and analysis of chronic lymphocytic leukemia (CLL) .

HY-177648

Nelitolimod	Toll-like Receptor (TLR)	Cancer
Nelitolimod, a CpG oligonucleotide, is a TLR9 agonist.

HY-150219

ODN M326 CpG-ODN M326	Toll-like Receptor (TLR)	Inflammation/Immunology
ODN M326 (CpG-ODN M326) is a potent *TLR9* agonist. ODN M326 induces the production of TNF. ODN M326 can be used as a vaccine adjuvant .

HY-150741A

Biotin-labeled ODN 2216 sodium	Toll-like Receptor (TLR)	Inflammation/Immunology
Biotin-labeled ODN 2216 (sodium) is a human-specific *TLR9* (toll-like receptor 9) ligand or agonist. Biotin-labeled ODN 2216 (sodium) can be used to evaluate CpG ODN cellular uptake and localization using a biotin detection system and light microscopy.

HY-150742

ODN 2336	Toll-like Receptor (TLR)	Inflammation/Immunology
ODN 2336 is a A-Class CpG ODN (oligodeoxynucleotides), is a potent *TLR9* agonist. ODN 2336 induces the production of IFN-α. ODN 2336 up-regulates the expression of IP-10 mRNA and IL-18 mRNA. ODN 2336 can be used as adjuvant of vaccines .

HY-177648A

Nelitolimod sodium	Toll-like Receptor (TLR)	Cancer
Nelitolimod sodium, a CpG oligonucleotide, is a TLR9 agonist.

HY-150748

ODN D-SL01	Toll-like Receptor (TLR)	Inflammation/Immunology Cancer
ODN D-SL01, a class B CpG ODN (oligodeoxynucleotide), is a *TLR9* agonist. ODN D-SL01 has strong immunostimulatory activity in a variety of vertebrate species and has anticancer activity. ODN D-SL01 sequence: 5'- T-C-G-C-G-A-C-G-T-T-C-G-C-C-C-G-A-C-G-T-T-C-G-G-T-A-3' .

HY-160040

Cobitolimod	Toll-like Receptor (TLR)	Inflammation/Immunology
Cobitolimod is a DNA oligonucleotide agonist of *TLR-9* with anti-inflammatory activity. Cobitolimod suppresses Th17 cells and induces anti-inflammatory FoxP3 and IL-10 expression, inhibiting the IL-17 signaling pathway .

HY-177635A

GNKG168 sodium	Toll-like Receptor (TLR)	Cancer
GNKG168 sodium is a synthetic, 21-mer, unmethylated CpG oligodeoxynucleotide. It acts as a TLR9 agonist with immunostimulatory activity.

HY-177635

GNKG168	Toll-like Receptor (TLR)	Cancer
GNKG168 is a synthetic, 21-mer, unmethylated CpG oligodeoxynucleotide. It acts as a TLR9 agonist with immunostimulatory activity.

HY-177642A

Litenimod sodium Li28 sodium sodium	Toll-like Receptor (TLR)	Cancer
Litenimod sodium is potent type B agonist of toll Like receptor 9 (TLR9), triggering both innate and adaptive immune response.

HY-177642

Litenimod Li28	Toll-like Receptor (TLR)	Cancer
Litenimod is potent type B agonist of toll Like receptor 9 (TLR9), triggering both innate and adaptive immune response.

HY-150724A

Biotin-labeled ODN 1018 sodium	Toll-like Receptor (TLR)	Inflammation/Immunology
Biotin-labeled ODN 1018 (sodium), an oligodeoxynucleotide, is a *TLR-9* agonist. Biotin-labeled ODN 1018 (sodium) can be used to evaluate CpG ODN cellular uptake and localization using a biotin detection system and light microscopy.

HY-150219A

ODN M326 sodium CpG-ODN M326 sodium	Toll-like Receptor (TLR)	Inflammation/Immunology
ODN M326 (CpG-ODN M326) sodium is a potent *TLR9* agonist. ODN M326 sodium induces TNF production and serves as a vaccine adjuvant .

HY-160040A

Cobitolimod sodium	Toll-like Receptor (TLR)	Inflammation/Immunology
Cobitolimod sodium is a DNA oligonucleotide agonist of *TLR-9* with anti-inflammatory activity. Cobitolimod sodium inhibits Th17 cells and induces anti-inflammatory FoxP3 and IL-10 expression, inhibiting the IL-17 signaling pathway .

HY-150726A

Biotin-labeled ODN 1668 sodium	Toll-like Receptor (TLR)	Inflammation/Immunology
Biotin-labeled ODN 1668 (sodium), a class B CpG ODN (oligodeoxynucleotide), is a *TLR9* agonist. Biotin-labeled ODN 1668 (sodium) can be used to evaluate CpG ODN cellular uptake and localization using a biotin detection system and light microscopy.

HY-146244B

FITC-labeled agatolimod sodium	Toll-like Receptor (TLR)	Inflammation/Immunology
FITC-labeled agatolimod (sodium), a class B CpG ODN (oligodeoxynucleotide), is a *TLR9* agonist. FITC-labeled agatolimod (sodium) can be used to evaluate CpG ODN cellular uptake and localization by confocal laser-scanning microscopy (excitation 495 nm, emission 520 nm) or flow cytometry.

HY-146245B

FITC-labeled ODN 1826 sodium	Toll-like Receptor (TLR)	Inflammation/Immunology
FITC-labeled ODN 1826 (sodium), a class B CpG ODN (oligodeoxynucleotide), is a *TLR9* agonist. FITC-labeled ODN 1826 (sodium) can be used to evaluate CpG ODN cellular uptake and localization by confocal laser-scanning microscopy (excitation 495 nm, emission 520 nm) or flow cytometry.

HY-150726B

FITC-labeled ODN 1668 sodium	Toll-like Receptor (TLR)	Inflammation/Immunology
FITC-labeled ODN 1668 (sodium), a class B CpG ODN (oligodeoxynucleotide), is a *TLR9* agonist. FITC-labeled ODN 1668 (sodium) can be used to evaluate CpG ODN cellular uptake and localization by confocal laser-scanning microscopy (excitation 495 nm, emission 520 nm) or flow cytometry.

HY-101929R

CU-CPT17e (Standard)	Reference Standards Toll-like Receptor (TLR)	Inflammation/Immunology Cancer
CU-CPT17e (Standard) is the analytical standard of CU-CPT17e (HY-101929). This product is intended for research and analytical applications. CU-CPT17e is a potent multi-Toll-like receptor (TLR) agonist that activates TLR3, TLR8, and TLR9.

Cat. No.	Product Name	Target	Research Area	Image

HY-P991257

MK-1966 1 Publications Verification	Interleukin Related CXCR MHC	Cancer
MK-1966 is an anti-IL-10 antibody. MK-1966 inhibits secretion of cytokines from activated macrophages, production of CC and CXC chemokines, and a TH1 response, down-regulates MHC and costimulatory molecules on dendritic cells (DCs), and induces regulatory T cells. MK-1966 can be used for the research of cancer , such as gastric cancer .

Cat. No.	Product Name		Classification

HY-146245

ODN 1826 Maximum Cited Publications 10 Publications Verification CpG 1826		CpG ODNs
ODN 1826 is a class B CpG ODN (oligodeoxynucleotide) and *TLR9* agonist. ODN 1826 induces NO and iNOS production and enhances Apoptosis. ODN 1826 enhances immune surveillance. ODN 1826 increases aortic atherosclerotic plaque size. ODN 1826 has antitumor activity against lung cancer, glioma and melanoma .

HY-146244

Agatolimod 1 Publications Verification ODN 2006; PF-3512676; CpG 7909; ODN 7909		CpG ODNs
Agatolimod ((ODN 2006; PF-3512676; CpG 7909)) is a *TLR9* agonist and immunomodulator with an EC₅₀ of 180 nM against human *TLR9. Agatolimod activates and upregulates the expression of both TLR9* and *TLR6, and mediates downstream signaling pathways via IRAK4, IRF5, IRF7. Agatolimod induces Th1-type innate and adaptive immune responses, activates various immune cells and promotes antigen presentation, regulates antibody levels and immune cell infiltration, upregulates the secretion of multiple cytokines, induces apoptosis and cell cycle arrest, enhances cytotoxicity, and clears intracellular Salmonella. Agatolimod is applicable to research on COVID-19*, breast cancer, lung adenocarcinoma, HPV-related tumors, melanoma, and salmonellosis .

HY-150724

ODN 1018 2 Publications Verification 1018 ISS		CpG ODNs
ODN 1018 (1018 ISS) is a *TLR9* agonist and immune modulator. ODN 1018 exhibits adjuvant activity and augments CD8+ T cell responses with LNP-encapsulated OVA peptides. ODN 1018 triggers sustained suppression of allergic airway inflammation. ODN 1018 can be used for the research of allergic asthma and systemic lupus erythematosus .

HY-150218

Agatolimod sodium 1 Publications Verification ODN 2006 sodium; ODN 7909 sodium; PF-3512676 sodium; CpG 7909 sodium		CpG ODNs
Agatolimod sodium (ODN 2006) is a class B CpG ODN and is a *TLR9* agonist. Agatolimod sodium can be used as vaccine adjuvant. Agatolimod sodium can be used for the research of cancer. Sequence: 5’-TCGTCGTTTTGTCGTTTTGTCGTT-3’ .

HY-150743

ODN 2395		CpG ODNs
ODN 2395 is a C class oligodeoxynucleotide and can be used as vaccine adjuvant. ODN 2395 is also a *TLR9* agonist. ODN 2395 can be used in the research of immunological vaccines. Sequence: 5'-tcgtcgttttcggcgc:gcgccg-3' (Note: The bases are phosphorothioate; ODN 2395 contains the partial palindromic sequence cggcgc:gcgccg) .

HY-146245C

ODN 1826 sodium Maximum Cited Publications 10 Publications Verification CpG 1826 sodium		CpG ODNs
ODN 1826 sodium is a class B CpG ODN (oligodeoxynucleotide) and *TLR9* agonist. ODN 1826 sodium induces NO and iNOS production and enhances Apoptosis. ODN 1826 sodium enhances immune surveillance. ODN 1826 sodium increases aortic atherosclerotic plaque size. ODN 1826 sodium has antitumor activity against lung cancer, glioma and melanoma .

HY-150741

ODN 2216 1 Publications Verification		CpG ODNs
ODN 2216 is a type A CpG oligodeoxynucleotide vaccine adjuvant and a *TLR9* agonist. ODN 2216 interacts with *TLR9* in the lysosomes of CD4 ⁺ T cells and activates feedback-dependent signaling pathways. ODN 2216 induces the production of type I interferons, IL-6 and TGF-β via the IRAK4/IRF7 axis, while increasing intracellular ATP levels. ODN 2216 not only induces the differentiation of CD4 ⁺ T cells into anti-inflammatory Th3-like regulatory phenotypes to inhibit autologous proliferation, but also enhances the specific CD8 ⁺ T cell-mediated cytotoxicity against Mammaglobin-A in breast cancer cells. ODN 2216 is widely used in studies related to breast cancer and systemic lupus erythematosus .

HY-150750

ODN M362		CpG ODNs
ODN M362, a class C oligodeoxynucleotide, is a *TLR-9* agonist and can be used as a vaccine adjuvant. ODN M362 induces cancer cell apoptosis .

HY-150724C

ODN 1018 sodium 2 Publications Verification 1018 ISS sodium		CpG ODNs
ODN 1018 (1018 ISS) sodium is a *TLR9* agonist and immune modulator. ODN 1018 sodium exhibits adjuvant activity and augments CD8+ T cell responses with LNP-encapsulated OVA peptides. ODN 1018 sodium triggers sustained suppression of allergic airway inflammation. ODN 1018 sodium can be used for the research of allergic asthma and systemic lupus erythematosus .

HY-150741C

ODN 2216 sodium 1 Publications Verification		CpG ODNs
ODN 2216 sodium is a type A CpG oligodeoxynucleotide vaccine adjuvant and a *TLR9* agonist. ODN 2216 sodium interacts with *TLR9* in the lysosomes of CD4 ⁺ T cells and activates feedback-dependent signaling pathways. ODN 2216 sodium induces the production of type I interferons, IL-6 and TGF-β via the IRAK4/IRF7 axis, while increasing intracellular ATP levels. ODN 2216 sodium not only induces the differentiation of CD4 ⁺ T cells into anti-inflammatory Th3-like regulatory phenotypes to inhibit autologous proliferation, but also enhances the specific CD8 ⁺ T cell-mediated cytotoxicity against Mammaglobin-A in breast cancer cells. ODN 2216 sodium is widely used in studies related to breast cancer and systemic lupus erythematosus .

HY-150217

CpG ODN 10101 2 Publications Verification ODN 10101		CpG ODNs
CpG ODN 10101 (ODN 10101; CPG 10101) is a selective agonist targeting TLR9, a synthetic oligodeoxynucleotide modified with phosphate thioester. CpG ODN 10101 activates B cells and plasmacytoid dendritic cells (pDCs), inducing the production of cytokines and chemokines such as interferon-IFN-α, interferon-inducible protein IP-10, and 2'5'-oligoadenylate synthase (2'5'-OAS), regulating innate immunity and promoting Th1 adaptive immune responses. CpG ODN 10101 also possesses antiviral properties and enhances vaccine immunogenicity, making it suitable as an immunomodulator and vaccine adjuvant for vaccine development in chronic hepatitis C and infectious diseases such as melioidosis, pertussis, and respiratory syncytial virus (RSV) .

HY-150726

ODN 1668 1 Publications Verification		CpG ODNs
ODN 1668, a class B CpG ODN (oligodeoxynucleotide), is a *TLR-9* agonist. ODN 1668 has strong immune regulatory properties, can enhance the level of antibody IgG2 subtype, promote the immune response of T cells and B cells, and can be used in the study of vaccine adjuvants. In addition, CpG ODN 1668 induces an antimicrobial immune response via a CaTLR9 dependent pathway in groupers. Sequence: 5'-tccatgacgttcctgatgct-3’ .

HY-150726C

ODN 1668 sodium 1 Publications Verification		CpG ODNs
ODN 1668 sodium, a class B CpG ODN (oligodeoxynucleotide), is a *TLR-9* agonist. ODN 1668 sodium has strong immune regulatory properties, can enhance the level of antibody IgG2 subtype, promote the immune response of T cells and B cells, and can be used in the study of vaccine adjuvants. In addition, CpG ODN 1668 sodium induces an antimicrobial immune response via a CaTLR9 dependent pathway in groupers. Sequence: 5'-tccatgacgttcctgatgct-3’ .

HY-150750A

ODN M362 sodium		CpG ODNs
ODN M362 sodium is a *TLR9* agonist that acts as a vaccine adjuvant. ODN M362 sodium activates mouse splenocytes, induces apoptosis in human hepatocellular carcinoma cells, upregulates proinflammatory cytokines in human hepatocellular carcinoma cells, and inhibits the proliferation of human hepatocellular carcinoma cells. ODN M362 sodium upregulates the expression of *TLR9/TLR6*, activates downstream signaling pathways via IRAK4 and IRF7, and strongly amplifies antigen-specific cellular immune responses to participate in innate immune activation. ODN M362 sodium can be used in research related to hepatocellular carcinoma and breast cancer .

HY-150217A

CpG ODN 10101 sodium 2 Publications Verification ODN 10101 sodium		CpG ODNs
CpG ODN 10101 sodium, a synthetic oligodeoxynucleotide (ODN), is a toll-like receptor 9 (TLR9) agonist. CpG ODN 10101 sodium is a potent inducer of cytokine/chemokine expression ex vivo when used in combination with HH2(VQLRIRVAVIRA-NH2). CpG ODN 10101 sodium induces IFN- secretion from dendritic cells (DCs) and stimulates B-cells.CpG ODN 10101 sodium has antiviral and immunomodulatory properties that can influence chronic infection with HCV .

HY-150748A

ODN D-SL01 sodium		CpG ODNs
ODN D-SL01 sodium, a class B CpG ODN (oligodeoxynucleotide), is a *TLR9* agonist. ODN D-SL01 sodium has strong immunostimulatory activity in a variety of vertebrate species and has anticancer activity. ODN D-SL01 sequence: 5'- T-C-G-C-G-A-C-G-T-T-C-G-C-C-C-G-A-C-G-T-T-C-G-G-T-A-3' .

HY-150724B

FITC-labeled ODN 1018 sodium		CpG ODNs
FITC-labeled ODN 1018 (sodium),an oligodeoxynucleotide, is a *TLR-9* agonist. FITC-labeled ODN 1018 (sodium) can be used to evaluate CpG ODN cellular uptake and localization by confocal laser-scanning microscopy (excitation 495 nm, emission 520 nm) or flow cytometry.

HY-150743A

Biotin-labeled ODN 2395 sodium		CpG ODNs
Biotin-labeled ODN 2395 (sodium), a C class oligodeoxynucleotide, is a *TLR9* agonist. Biotin-labeled ODN 2395 (sodium) can be used to evaluate CpG ODN cellular uptake and localization using a biotin detection system and light microscopy.

HY-148511A

Vidutolimod sodium CMP-001 sodium		CpG ODNs
Vidutolimod sodium is a CpG-A oligodeoxynucleotide. Vidutolimod sodium is a Toll-like receptor 9 (TLR9) agonist, which activates plasmacytoid dendritic cells (pDCs) and triggers interferon alpha (IFNα) release, leading to a cascade of anti-tumor immune effects.

HY-146245F

FAM-labeled ODN 1826 sodium 1 Publications Verification		CpG ODNs
FAM-labeled ODN 1826 sodium, a class B CpG ODN (oligodeoxynucleotide), is a *TLR9* agonist. FAM-labeled ODN 1826 sodium can be used to evaluate CpG ODN cellular uptake and localization by confocal laser-scanning microscopy or flow cytometry.

HY-146245A

Biotin-labeled ODN 1826 sodium		CpG ODNs
Biotin-labeled ODN 1826 (sodium), a class B CpG ODN (oligodeoxynucleotide), is a *TLR9* agonist. Biotin-labeled ODN 1826 (sodium) can be used to evaluate CpG ODN cellular uptake and localization using a biotin detection system and light microscopy.

HY-150743C

ODN 2395 sodium		CpG ODNs
ODN 2395 sodium is a C class oligodeoxynucleotide and can be used as vaccine adjuvant. ODN 2395 sodium is also a *TLR9* agonist. ODN 2395 sodium can be used in the research of immunological vaccines. Sequence: 5'-tcgtcgttttcggcgc:gcgccg-3' .

HY-150743B

FITC-labeled ODN 2395 sodium		CpG ODNs
FITC-labeled ODN 2395 (sodium), a C class oligodeoxynucleotide, is a *TLR9* agonist. FITC-labeled ODN 2395 (sodium) can be used to evaluate CpG ODN cellular uptake and localization by confocal laser-scanning microscopy (excitation 495 nm, emission 520 nm) or flow cytometry.

HY-150742A

ODN 2336 sodium		CpG ODNs
ODN 2336 sodium is a A-Class CpG ODN (oligodeoxynucleotides), is a potent *TLR9* agonist. ODN 2336 sodium induces the production of IFN-α. ODN 2336 sodium up-regulates the expression of IP-10 mRNA and IL-18 mRNA. ODN 2336 sodium can be used as adjuvant of vaccines .

HY-150212

Tilsotolimod IMO-2125		Antisense Oligonucleotides
Tilsotolimod (IMO-2125) is a *TLR9* agonist. Tilsotolimod activates the *TLR9* signaling pathway, triggers downstream pro-inflammatory and immunostimulatory pathways, enhances the uptake and killing of cancer cells, and induces adaptive immune responses. Tilsotolimod is applicable to research related to melanoma and colorectal cancer .

HY-150212A

Tilsotolimod sodium IMO-2125 sodium		Antisense Oligonucleotides
Tilsotolimod (IMO-2125) sodium is a *TLR9* agonist. Tilsotolimod sodium activates the *TLR9* signaling pathway, triggers downstream pro-inflammatory and immunostimulatory pathways, enhances the uptake and killing of cancer cells, and induces adaptive immune responses. Tilsotolimod sodium is applicable to research related to melanoma and colorectal cancer .

HY-146244A

Biotin-labeled agatolimod sodium		CpG ODNs
Biotin-labeled agatolimod (sodium), a class B CpG ODN (oligodeoxynucleotide), is a *TLR9* agonist. Biotin-labeled agatolimod (sodium) can be used to evaluate CpG ODN cellular uptake and localization using a biotin detection system and light microscopy.

HY-150741B

FITC-labeled ODN 2216 sodium		CpG ODNs
FITC-labeled ODN 2216 (sodium) is a human-specific *TLR9* (toll-like receptor 9) ligand or agonist. FITC-labeled ODN 2216 (sodium) can be used to evaluate CpG ODN cellular uptake and localization by confocal laser-scanning microscopy (excitation 495 nm, emission 520 nm) or flow cytometry.

HY-177058

DSP30		CpG ODNs
DSP30 is a phosphorothioate cpG-oligodeoxynucleotide and a *TLR9* agonist. DSP30 can activate immune system cells, including B cells and dendritic cells, by inducing proliferation and cytokine production.DSP30 can enhance the immunosuppressive function of bone marrow-multipotent mesenchymal stromal cells (BM-MSC). DSP30 combined with interleukin 2 (IL2) is an effective mitotic stimulant in B-cell disorders. DSP30 can be used for the genetic characteristic research and analysis of chronic lymphocytic leukemia (CLL) .

HY-177648

Nelitolimod		CpG ODNs
Nelitolimod, a CpG oligonucleotide, is a TLR9 agonist.

HY-150219

ODN M326 CpG-ODN M326		CpG ODNs
ODN M326 (CpG-ODN M326) is a potent *TLR9* agonist. ODN M326 induces the production of TNF. ODN M326 can be used as a vaccine adjuvant .

HY-150741A

Biotin-labeled ODN 2216 sodium		CpG ODNs
Biotin-labeled ODN 2216 (sodium) is a human-specific *TLR9* (toll-like receptor 9) ligand or agonist. Biotin-labeled ODN 2216 (sodium) can be used to evaluate CpG ODN cellular uptake and localization using a biotin detection system and light microscopy.

HY-150742

ODN 2336		CpG ODNs
ODN 2336 is a A-Class CpG ODN (oligodeoxynucleotides), is a potent *TLR9* agonist. ODN 2336 induces the production of IFN-α. ODN 2336 up-regulates the expression of IP-10 mRNA and IL-18 mRNA. ODN 2336 can be used as adjuvant of vaccines .

HY-177648A

Nelitolimod sodium		CpG ODNs
Nelitolimod sodium, a CpG oligonucleotide, is a TLR9 agonist.

HY-150748

ODN D-SL01		CpG ODNs
ODN D-SL01, a class B CpG ODN (oligodeoxynucleotide), is a *TLR9* agonist. ODN D-SL01 has strong immunostimulatory activity in a variety of vertebrate species and has anticancer activity. ODN D-SL01 sequence: 5'- T-C-G-C-G-A-C-G-T-T-C-G-C-C-C-G-A-C-G-T-T-C-G-G-T-A-3' .

HY-160040

Cobitolimod		Antisense Oligonucleotides
Cobitolimod is a DNA oligonucleotide agonist of *TLR-9* with anti-inflammatory activity. Cobitolimod suppresses Th17 cells and induces anti-inflammatory FoxP3 and IL-10 expression, inhibiting the IL-17 signaling pathway .

HY-177635A

GNKG168 sodium		Antisense Oligonucleotides
GNKG168 sodium is a synthetic, 21-mer, unmethylated CpG oligodeoxynucleotide. It acts as a TLR9 agonist with immunostimulatory activity.

HY-177635

GNKG168		Antisense Oligonucleotides
GNKG168 is a synthetic, 21-mer, unmethylated CpG oligodeoxynucleotide. It acts as a TLR9 agonist with immunostimulatory activity.

HY-177642A

Litenimod sodium Li28 sodium sodium		CpG ODNs
Litenimod sodium is potent type B agonist of toll Like receptor 9 (TLR9), triggering both innate and adaptive immune response.

HY-177642

Litenimod Li28		CpG ODNs
Litenimod is potent type B agonist of toll Like receptor 9 (TLR9), triggering both innate and adaptive immune response.

HY-150724A

Biotin-labeled ODN 1018 sodium		CpG ODNs
Biotin-labeled ODN 1018 (sodium), an oligodeoxynucleotide, is a *TLR-9* agonist. Biotin-labeled ODN 1018 (sodium) can be used to evaluate CpG ODN cellular uptake and localization using a biotin detection system and light microscopy.

HY-150219A

ODN M326 sodium CpG-ODN M326 sodium		CpG ODNs
ODN M326 (CpG-ODN M326) sodium is a potent *TLR9* agonist. ODN M326 sodium induces TNF production and serves as a vaccine adjuvant .

HY-160040A

Cobitolimod sodium		Antisense Oligonucleotides
Cobitolimod sodium is a DNA oligonucleotide agonist of *TLR-9* with anti-inflammatory activity. Cobitolimod sodium inhibits Th17 cells and induces anti-inflammatory FoxP3 and IL-10 expression, inhibiting the IL-17 signaling pathway .

HY-150726A

Biotin-labeled ODN 1668 sodium		CpG ODNs
Biotin-labeled ODN 1668 (sodium), a class B CpG ODN (oligodeoxynucleotide), is a *TLR9* agonist. Biotin-labeled ODN 1668 (sodium) can be used to evaluate CpG ODN cellular uptake and localization using a biotin detection system and light microscopy.

HY-146244B

FITC-labeled agatolimod sodium		CpG ODNs
FITC-labeled agatolimod (sodium), a class B CpG ODN (oligodeoxynucleotide), is a *TLR9* agonist. FITC-labeled agatolimod (sodium) can be used to evaluate CpG ODN cellular uptake and localization by confocal laser-scanning microscopy (excitation 495 nm, emission 520 nm) or flow cytometry.

HY-146245B

FITC-labeled ODN 1826 sodium		CpG ODNs
FITC-labeled ODN 1826 (sodium), a class B CpG ODN (oligodeoxynucleotide), is a *TLR9* agonist. FITC-labeled ODN 1826 (sodium) can be used to evaluate CpG ODN cellular uptake and localization by confocal laser-scanning microscopy (excitation 495 nm, emission 520 nm) or flow cytometry.

HY-150726B

FITC-labeled ODN 1668 sodium		CpG ODNs
FITC-labeled ODN 1668 (sodium), a class B CpG ODN (oligodeoxynucleotide), is a *TLR9* agonist. FITC-labeled ODN 1668 (sodium) can be used to evaluate CpG ODN cellular uptake and localization by confocal laser-scanning microscopy (excitation 495 nm, emission 520 nm) or flow cytometry.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: